sprite-preloader
Anzeige
Mehr »
Donnerstag, 27.06.2019 Börsentäglich über 12.000 News von 613 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2AG0F ISIN: SE0006091997 Ticker-Symbol: 1YR 
Aktie:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
1-Woche-Intraday-Chart
IMMUNOVIA AB 1-Woche-Intraday-Chart
05.11.2018 | 17:16
(4 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

LUND, Sweden, Nov 5, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET.

Immunovia invites to a teleconference (in English) for investors, analysts and media on November 7, at 4:30 - 5:30 p.m. CET. Mats Grahn, CEO will present Immunovia and comment on the interim report followed by a Q&A-session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below from:

Telephone:

SE: +46856642662

CH: +41225675548

DE: +4969222229046

DK: +4582333178

FR: +33170750712

UK: +442030089803

NO: +4723500254

US: +16465025116

BE: +3224040635

NL: +31207168416

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For questions or interview bookings: ir@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.

(Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

CONTACT:

Immunovia AB

Medicon Village Scheelevägen 2 SE-223 81 Lund

+46-46-275-60-00

http://www.immunovia.com

info@immunovia.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january-september-2018-on-november-7--2018,c2664423

The following files are available for download:

http://mb.cision.com/Main/13121/2664423/939419.pdf

Immunovia telephone conference Q3 2018


© 2018 PR Newswire